Open AccessSafety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B
Author(s) -
Jeffrey T. Guptill,
Shruti Raja,
Vern C. Juel,
Emmanuel B. Walter,
Michael CohenWolkowiez,
Heather Hill,
Eli A. Sendra,
B. Hauser,
Paul J. Jackson,
Geeta K. Swamy
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02329-20
Subject(s) - tolerability , medicine , immunogenicity , pharmacokinetics , placebo , adverse effect , dosing , pharmacology , cmax , botulism , immunology , antibody , gastroenterology , pathology , biology , alternative medicine , genetics
Botulism is a rare, life-threatening paralytic disease caused byClostridium botulinum neurotoxin (BoNT). Available treatments, including an equine antitoxin and human immune globulin, are given postexposure and challenging to produce and administer.